InfoDesk

Monitoring and audit get mentioned in the same breath so often that the two start to sound like the same activity. They are not. Monitoring is the continuous, mandatory oversight of a trial while it is running: checking that protocol is being followed, subjects are protected, and data are accurate. Audit is different. It is an independent, periodic review that steps back from any single trial and asks whether the quality system producing that trial is actually working.

Of the three, this is the closest thing to an official ‘inspection database’. Through its Data Dashboard, FDA publishes final classifications – No Action Indicated (NAI), Voluntary Action Indicated (VAI), or Official Action Indicated (OAI) – for each project area of an inspection, updated weekly. It’s a genuinely useful starting point, but the classification is a summary judgment, not a citation-level record.

Inspection readiness is the state of being able to withstand an FDA drug manufacturing inspection at any time, with no advance notice, because compliance is built into daily operations rather than assembled at the last minute before a visit arrives. It matters more now than it once did: unannounced inspections are more common, and data integrity has become a permanent line of questioning.

Health authorities around the world are issuing more guidance, policy updates, and enforcement actions than ever before, and life sciences organizations are expected to track all of it without missing a signal. Choosing the right regulatory intelligence solution has become one of the highest-stakes technology decisions a regulatory affairs, quality, or compliance leader will make this year.

Pharmaceutical regulatory inspection and enforcement trends –  what QA, GxP and compliance teams, partners and vendors need to know in 2026? Pharmaceutical regulatory inspection and enforcement activity has intensified sharply across the FDA, MHRA, and EMA over the past year, with warning letters, foreign site inspections, and data integrity findings all trending upward at the same time.

Inspection readiness is the ability to withstand a regulatory inspection of a site at any time, without advance warning and without a scramble to pull records together. It means your quality systems, documentation, and personnel consistently meet the standard a regulator expects, as a matter of daily operation rather than a one-time exercise.

These ten principles are not siloed – in a functioning quality system, they interact constantly. A training gap under People can surface as a documentation error, which in turn triggers a deviation investigation under Compliance & recalls. This is why GMP is operationalized in practice through a Pharmaceutical Quality System (PQS): the structured framework that connects all ten principles into a single, auditable system rather than ten disconnected activities.

In Infodesk’s latest Regulatory Forum session, “The evolution of quality intelligence activation,” we picked up a conversation that started at the RAPS Regulatory Intelligence Conference in Baltimore in March. That discussion — summarized here — explored how quality intelligence is maturing from an inspection-readiness function into a strategic capability for enterprise regulatory risk management.

Signals vs. Trends: How to Spot What’s Coming Before Your Competitors Do A practical playbook for telling a faint signal from a real trend, and turning either one into action your leadership will actually use.

AI is becoming part of the everyday reality of Regulatory Intelligence teams in life sciences organizations. What once felt experimental is now supporting practical work across monitoring, triage and interpretation, summarization, impact assessment, communication, and workflow management.